Outlook Therapeutics, Inc. OTLK 深 沪
已收盘 02-06 16:00:00 美东时间
0.4327
+0.043
+10.95%
华盛通- 最 高2.03
- 今 开0.3971
- 成交量 115.42万股
- 最 低 0.3809
- 昨 收 0.39
- 总市值 9.78万
- 52周最高 2.03
- 市盈率 静 --
- 换手率 510.69%
- 52周最低 0.00
- 委 比 23.43%
- 总股本 0.00亿
- 历史最高 2.03
- 量 比 0.94
- 振 幅 422.85%
- 历史最低 0.00
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.
01-02 21:18
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Shares of Baidu Inc (NASDAQ:BIDU) rose sharply in pre-market trading after the ...
01-02 17:30
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday (CORRECTED)
U.S. stock futures up, Apple reduces Vision Pro production, TSMC gets U.S. export license, VS Media announces share combination.
01-02 15:19
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Outlook Therapeutics will participate in a Virtual Investor Lunch Break Event on June 25th at 12:00 PM ET. Lawrence Kenyon, Jeff Evanson, and Jedd Comiskey will discuss the company’s commercial strategy, upcoming milestones, and current activities. A live webcast and replay will be available on the company’s website. Outlook Therapeutics is focused on advancing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases.
2025-06-18 13:05
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
Outlook Therapeutics, Inc. launched an underwritten public offering of its common stock and warrants to raise funds for working capital and general corporate purposes. The company aims to commercialize its LYTENAVA™ (bevacizumab gamma) in the EU and UK in Q2 2025 and pursue U.S. approval for its ophthalmic bevacizumab formulation.
2025-05-22 20:01
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $33
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $35 to $33.
2024-09-03 18:16
